학술논문
Long-term outcomes of the global tuberculosis and COVID-19 co-infection cohort.
Document Type
Academic Journal
Author
Casco N; Jorge AL; Palmero DJ; Alffenaar JW; Fox GJ; Ezz W; Cho JG; Denholm J; Skrahina A; Solodovnikova V; Arbex MA; Alves T; Rabahi MF; Pereira GR; Sales R; Silva DR; Saffie MM; Salinas NE; Miranda RC; Cisterna C; Concha C; Fernandez I; Villalón C; Vera CG; Tapia PG; Cancino V; Carbonell M; Cruz A; Muñoz E; Muñoz C; Navarro I; Pizarro R; Cristina Sánchez GP; Vergara Riquelme MS; Vilca E; Soto A; Flores X; Garavagno A; Bahamondes MH; Merino LM; Pradenas AM; Revillot ME; Rodriguez P; Salinas AS; Taiba C; Valdés JF; Subiabre JN; Ortega C; Palma S; Castillo PP; Pinto M; Bidegain FR; Venegas M; Yucra E; Li Y; Cruz A; Guelvez B; Victoria Plaza R; Tello Hoyos KY; Cardoso-Landivar J; Van Den Boom M; Andréjak C; Blanc FX; Dourmane S; Froissart A; Izadifar A; Rivière F; Schlemmer F; Manika K; Diallo BD; Hassane-Harouna S; Artiles N; Mejia LA; Gupta N; Ish P; Mishra G; Patel JM; Singla R; Udwadia ZF; Alladio F; Angeli F; Calcagno A; Centis R; Codecasa LR; De Lauretis A; Esposito SMR; Formenti B; Gaviraghi A; Giacomet V; Goletti D; Gualano G; Matteelli A; Migliori GB; Motta I; Palmieri F; Pontali E; Prestileo T; Riccardi N; Saderi L; Saporiti M; Sotgiu G; Spanevello A; Stochino C; Tadolini M; Torre A; Villa S; Visca D; Kurhasani X; Furjani M; Rasheed N; Danila E; Diktanas S; Ridaura RL; Luna López FL; Torrico MM; Rendon A; Akkerman OW; Chizaram O; Al-Abri S; Alyaquobi F; Althohli K; Aguirre S; Teixeira RC; De Egea V; Irala S; Medina A; Sequera G; Sosa N; Vázquez F; Llanos-Tejada FK; Manga S; Villanueva-Villegas R; Araujo D; Sales Marques RD; Socaci A; Barkanova O; Bogorodskaya M; Borisov S; Mariandyshev A; Kaluzhenina A; Vukicevic TA; Stosic M; Beh D; Ng D; Ong CWM; Solovic I; Dheda K; Gina P; Caminero JA; De Souza Galvão ML; Dominguez-Castellano A; García-García JM; Pinargote IM; Fernandez SQ; Sánchez-Montalvá A; Huguet ET; Murguiondo MZ; Bart PA; Mazza-Stalder J; D'Ambrosio L; Kamolwat P; Bakko F; Barnacle J; Bird S; Brown A; Chandran S; Killington K; Man K; Papineni P; Ritchie F; Tiberi S; Utjesanovic N; Zenner D; Hearn JL; Heysell S; Young L
Source
Publisher: European Respiratory Society Country of Publication: England NLM ID: 8803460 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 1399-3003 (Electronic) Linking ISSN: 09031936 NLM ISO Abbreviation: Eur Respir J Subsets: MEDLINE
Subject
Language
English
Abstract
Background: Longitudinal cohort data of patients with tuberculosis (TB) and coronavirus disease 2019 (COVID-19) are lacking. In our global study, we describe long-term outcomes of patients affected by TB and COVID-19.
Methods: We collected data from 174 centres in 31 countries on all patients affected by COVID-19 and TB between 1 March 2020 and 30 September 2022. Patients were followed-up until cure, death or end of cohort time. All patients had TB and COVID-19; for analysis purposes, deaths were attributed to TB, COVID-19 or both. Survival analysis was performed using Cox proportional risk-regression models, and the log-rank test was used to compare survival and mortality attributed to TB, COVID-19 or both.
Results: Overall, 788 patients with COVID-19 and TB (active or sequelae) were recruited from 31 countries, and 10.8% (n=85) died during the observation period. Survival was significantly lower among patients whose death was attributed to TB and COVID-19 versus those dying because of either TB or COVID-19 alone (p<0.001). Significant adjusted risk factors for TB mortality were higher age (hazard ratio (HR) 1.05, 95% CI 1.03-1.07), HIV infection (HR 2.29, 95% CI 1.02-5.16) and invasive ventilation (HR 4.28, 95% CI 2.34-7.83). For COVID-19 mortality, the adjusted risks were higher age (HR 1.03, 95% CI 1.02-1.04), male sex (HR 2.21, 95% CI 1.24-3.91), oxygen requirement (HR 7.93, 95% CI 3.44-18.26) and invasive ventilation (HR 2.19, 95% CI 1.36-3.53).
Conclusions: In our global cohort, death was the outcome in >10% of patients with TB and COVID-19. A range of demographic and clinical predictors are associated with adverse outcomes.
Competing Interests: Conflict of interest: The authors have no potential conflicts of interest to disclose.
(Copyright ©The authors 2023.)
Methods: We collected data from 174 centres in 31 countries on all patients affected by COVID-19 and TB between 1 March 2020 and 30 September 2022. Patients were followed-up until cure, death or end of cohort time. All patients had TB and COVID-19; for analysis purposes, deaths were attributed to TB, COVID-19 or both. Survival analysis was performed using Cox proportional risk-regression models, and the log-rank test was used to compare survival and mortality attributed to TB, COVID-19 or both.
Results: Overall, 788 patients with COVID-19 and TB (active or sequelae) were recruited from 31 countries, and 10.8% (n=85) died during the observation period. Survival was significantly lower among patients whose death was attributed to TB and COVID-19 versus those dying because of either TB or COVID-19 alone (p<0.001). Significant adjusted risk factors for TB mortality were higher age (hazard ratio (HR) 1.05, 95% CI 1.03-1.07), HIV infection (HR 2.29, 95% CI 1.02-5.16) and invasive ventilation (HR 4.28, 95% CI 2.34-7.83). For COVID-19 mortality, the adjusted risks were higher age (HR 1.03, 95% CI 1.02-1.04), male sex (HR 2.21, 95% CI 1.24-3.91), oxygen requirement (HR 7.93, 95% CI 3.44-18.26) and invasive ventilation (HR 2.19, 95% CI 1.36-3.53).
Conclusions: In our global cohort, death was the outcome in >10% of patients with TB and COVID-19. A range of demographic and clinical predictors are associated with adverse outcomes.
Competing Interests: Conflict of interest: The authors have no potential conflicts of interest to disclose.
(Copyright ©The authors 2023.)